Retooling for Modern Management of Progressive MS: An Interactive, Case-Based Activity

Fred D. Lublin, MD is the Saunders Family Professor of Neurology at The Icahn School of Medicine at Mount Sinai and Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at that institution.

Dr. Lublin received his medical degree in 1972 from Jefferson Medical College, Philadelphia, PA. He completed his internship in Internal Medicine from the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center.

As a neuroimmunologist, Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system. He has been involved in both basic science and clinical research. He and his colleagues were among the first in the country involved with studies of Interferon beta-1b, which was approved by the Food & Drug Administration in 1993 to treat the relapsing-remitting form of Multiple Sclerosis. He is currently involved with several new clinical research protocols on promising agents for treating various aspects of MS. He was chairman of the National MS Society (USA) advisory committee on clinical trials of new drugs in Multiple Sclerosis and the National Multiple Sclerosis Society’s Research Programs Advisory Committee. He was a member of the National MS Society National Board of Directors. He is past Chair of the New York City/Southern New York Chapter of NMSS Clinical Advisory Committee. He is a member of the International Medical & Scientific Board of the Multiple Sclerosis International Federation. Dr. Lublin and his colleagues at the National MS Society have re-defined the clinical course definitions of MS, updated in 2014. He has chaired a task force on the ethics of placebo-controlled trials in MS. Dr. Lublin is a member of the international panel that periodically redefines the diagnostic criteria for MS (McDonald Criteria). Dr. Lublin is co-chair of the National Institute of Neurological Diseases and Stroke MS Common Data Element committee and a member of their steering committee. He is a member of the WHO Advisory Group for the Revision of ICD-10 Diseases of the Nervous System working group on demyelinating diseases of the central nervous system. He was a Co-Chief and founding Editor of the journal Multiple Sclerosis and Related Disorders.

Dr. Lublin has published numerous scientific articles and is a member of many professional societies and advisory boards. Dr. Lublin has served as a consultant to the National Institutes of Health and to many pharmaceutical/biotech companies in all phases of new drug development and in preparation for presentation to the FDA and their advisory panels. He was the Principal Investigator of the NIH-sponsored multicenter Combination Therapy study in Multiple Sclerosis. In June of 2019, Dr. Lublin was awarded the June Halper Lifetime Achievement Award from the Consortium of Multiple Sclerosis Centers.

Dr. Aaron Miller graduated from Brandeis University in 1964 and received his MD degree from New York University School of Medicine in 1968. Following his residency in neurology at the Albert Einstein College of Medicine, he received additional postdoctoral training in neurovirology and immunology at the Johns Hopkins University School of Hygiene and Public Health and at the Albert Einstein College of Medicine. During this time he was the recipient of a fellowship from the National Multiple Sclerosis Society.

In March, 2004 Dr. Miller assumed the position of Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Icahn School of Medicine at Mount Sinai. For 23 years prior to that, he headed the Division of Neurology at Maimonides Medical Center in Brooklyn, New York, where he continued to serve as co-director of the Multiple Sclerosis Care Center until 2015. Dr. Miller is also a Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York.

Dr. Miller is currently Chairman of the National Medical Advisory Committee of the National MS Society, having previously served in that position from 2002-2010. He is a past president of the Consortium of MS Centers and was the first president of the Section on Multiple Sclerosis of the American Academy of Neurology. He has participated in numerous clinical trials of new treatments for MS. He has authored two books: Multiple Sclerosis in Clinical Practice, with colleagues Dr. Fred Lublin and Dr. Patricia Coyle, and Neuroimmunology as part of the What Do I Do Now? series with Dr. Tracy DeAngelis, and edited Handbook of Relapsing-Remitting Multiple Sclerosis. He has also published more than 95 articles in peer-reviewed journals, as well as many chapters on MS and other subjects in neurology.

Dr. Miller is also very active with the American Academy of Neurology (AAN). He served as a member of the Board of Directors from 2009 through 2017 and was secretary of the Board from 2013-2017. He completed 10 years as editor of Continuum, the bimonthly continuing education publication of the AAN, in 2012, and currently serves as editor of Continuum Audio.

Dr. Miller has been cited numerous times by New York magazine in its list of top doctors and has been continually included in Castle Connolly’s America’s Top Doctors from 2009-2018.

Claire Hopkins, MA, FRCS, DM is a Consultant Rhinologist at Guy’s Hospital, a large tertiary referral center in London, UK, with a clinical practice covering the breadth of rhinology including sinusitis, anterior skull base work, and facial plastics. She is a Professor at King’s College London. She is the Past-President of the British Rhinological Society, Academic Chair of ENTUK/BACO and the President elect of the Royal Society of Medicine’s Section of Laryngology and Rhinology. Dr. Hopkins is co-author of the European Position Statement on Rhinosinusitis and Nasal Polyps and the International Consensus on Rhinosinusitis. She has a large research program covering all aspects of medical and surgical management of rhinitis and sinus disease, with a focus on improving outcomes in the management of nasal polyps.